Dexmedetomidine (DEX), widely used for its sedative and sympatholytic properties, is now drawing attention for organ-protective effects during cardiac surgery with cardiopulmonary bypass (CPB). A systematic review and meta-analysis of nine randomized trials demonstrated that DEX significantly improved oxygenation index, reduced alveolar–arterial oxygen gradient, and lowered respiratory index compared to saline controls. Importantly, pro-inflammatory cytokines including IL-6 and TNF-α were markedly suppressed in the DEX group, underscoring its anti-inflammatory action during the perioperative period.
While early postoperative benefits were evident, CRP levels at 24 hours showed no significant difference, suggesting time-sensitive effects that warrant further study. These findings highlight DEX as more than a sedative, positioning it as a potential adjunct for pulmonary protection in…
